Please assess the completion status of the following clinical trial:

Trial Title: Study of QRH-882260 Heptapeptide Application in the Colon

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Subject meets at least one of the following criteria:~* At increased risk for colorectal cancer (CRC) and colonic polyps~* Known colonic adenomas scheduled for colonic resection~* Scheduled for outpatient colonoscopy for follow up surveillance of IBD with known dysplasia or who are at high risk for high grade dysplasia~* Subject is scheduled for outpatient colonoscopy in the Medical Procedures Unit at UMHS~* Subject is medically cleared for the procedure (e.g. washout for anticoagulants, co-morbidities) Standard practice guidelines for safely proceeding with the procedure will be sufficient for the study~* Age 18 to 100 years~* Willing and able to sign informed consent~Exclusion Criteria:~Subjects with known allergy or negative reaction to Cy5 (a near-infrared fluorophore) or derivatives~* Subjects on active chemotherapy or radiation treatment~* Pregnant or trying to conceive

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Topical QRH Heptapeptide Administration (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).